Background: Studies performed with schizophrenic adults who were resistant to classical neuroleptics showed improvement in 30% of the patients when treated with clozapine. Very early onset schizophrenic patients benefit only partially from conventional antipsychotics and are at increased risk of developing extrapyramidal symptoms; clozapine may offer an alternative treatment for these patients.
Methods: Eleven neuroleptic-resistant children (< 13 years) with schizophrenia were treated with clozapine. Improvement was monitored during the first 16 weeks using the Brief Psychiatric Rating Scale, Positive and Negative Syndrome Scale and Clinical Global Impression. The mean clozapine dosage was 227.3 (s.d. 34.4 mg/day at the end of the 16 weeks.
Results: There was an overall statistically significant reduction in all parameters, especially positive symptoms, implying a favourable outcome. Most of the improvement occurred during the first 6 to 8 weeks. The major side-effects were somnolence and drooling (no agranulocytosis).
Conclusion: Clozapine may be a promising drug for the treatment of resistant childhood-onset schizophrenia.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1192/bjp.170.6.507 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Neurocognitive dysfunctions in childhood-onset schizophrenia: A systematic review.
Schizophr Res Cogn
June 2025
University Department of Child and Adolescent Psychiatry, Children's Hospitals of NICE CHU-Lenval, Nice, France.
Objective: To conduct a systematic review of neurocognitive dysfunctions in patients with childhood-onset schizophrenia (COS), a neuropsychiatric disorder that occurs before age 13 and is rarer and more severe than adult-onset schizophrenia.
Method: A search was made in the PubMed database. Sixty-seven studies (out of 543) which analyzed Intellectual Quotient (IQ), attentional, memory and executive functions were selected by two independent researchers.
Prioritizing Brain Health in Youth: Bringing Neuroscience to Society and Informing Policy, Lessons Learnt from the European Brain Council Expert Meeting Held at the Federation of European Neuroscience Societies Forum 2024.
Eur J Neurosci
January 2025
European Brain Council, Brussels, Belgium.
Good brain health plays a significant role in an individual's well-being and profoundly impacts the collective economy and society. Brain development does not stop at birth, and some aspects continue throughout childhood and adolescence, allowing the full development of cognitive functions. Different determinants related to physical health, healthy environments, safety and security, life-long learning and social connection as well as access to quality services influence the way our brains develop, adapt and respond to stress and adversity.
View Article and Find Full Text PDFThe diagnostic conundrum of late-onset developmental regression in child psychiatry: case series.
BJPsych Open
January 2025
Department of Child and Adolescent Psychiatry, National Institute of Mental Health and Neurosciences, Bangalore, India.
Background: Developmental regression in children, in the absence of neurological damage or trauma, presents a significant diagnostic challenge. The complexity is further compounded when it is associated with psychotic symptoms.
Method: We discuss a case series of ten children aged 6-10 years, with neurotypical development, presenting with late-onset developmental regression (>6 years of age), their clinical course and outcome at 1 year.
Dissociative psychosis or dissociative schizophrenia? Comparison of two phenomena.
BMC Psychiatry
January 2025
Department of Psychiatry, University of Health Sciences, Erzurum City Hospital, Erzurum, 25100, Turkey.
Background: In recent years, researchers have reported crucial advances in the understanding of "Dissociative psychosis" and "Dissociative schizophrenia". While clinical studies in this area have been sustained for well, it remains to be established for some aspects that a clear and valid relationship exists between dissociation, childhood traumatic experiences, and schizophrenia or psychotic spectrum disorders.
Methods: To test such hypotheses, we divided the patients into two groups; the first group consisted of patients with psychotic disorders not otherwise specified (PNOS), and the second group consisted of schizophrenic patients.
Psychopathology trajectories and relapse in first episode schizophrenia with assured long-acting injectable adherence over 24 months.
Schizophr Res
January 2025
Faculty of Medicine and Health Sciences, Department of Psychiatry, Stellenbosch University, Tygerberg, 7500 Cape Town, South Africa.
Background: Relapse following a first episode of schizophrenia (FES) is common and often results in serious adverse psychosocial consequences. Treatment non-adherence is a key risk factor for relapse, but why relapse occurs despite antipsychotic treatment adherence remains unclear. This study examined the differences in FES psychopathology trajectories over 24-months with assured long-acting injectable antipsychotic (LAIA) treatment, to control for treatment adherence between those who relapsed and those who did not and what moderates these group differences.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!